^
MDM2 amplification
Liposarcoma
BI 907828
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
No biomarker
Liposarcoma
eribulin mesylate
Sensitive: A1 - Approval
No biomarker
Liposarcoma
trabectedin
Sensitive: A1 - Approval
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
PGR positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
No biomarker
Liposarcoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Liposarcoma
palbociclib
Sensitive: A2 - Guideline
PGR positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
PGR positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
No biomarker
Liposarcoma
selinexor
Sensitive: B - Late Trials
GRM1 overexpression
Liposarcoma
selinexor
Sensitive: B - Late Trials
CALB1 underexpression
Liposarcoma
selinexor
Sensitive: B - Late Trials
MDM2 amplification
Liposarcoma
APG-115
Sensitive: C2 – Inclusion Criteria
CDK4 amplification
Liposarcoma
palbociclib
Sensitive: C2 – Inclusion Criteria
MDM2 amplification
Liposarcoma
RAIN-32
Sensitive: C2 – Inclusion Criteria
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AZD5363
Sensitive: C3 – Early Trials
PIK3CA mutation
Liposarcoma
copanlisib
Sensitive: C3 – Early Trials
RB1 expression
Liposarcoma
palbociclib
Sensitive: C3 – Early Trials
CD70 expression
Uterine Corpus Leiomyosarcoma
ARX305
Sensitive: C3 – Early Trials
FUS-DDIT3 translocation
Liposarcoma
SP2577
Sensitive: C3 – Early Trials
MCM4 overexpression
Liposarcoma
PARP inhibitor
Sensitive: C3 – Early Trials
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
lorlatinib
Sensitive: C4 – Case Studies
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
alectinib
Sensitive: C4 – Case Studies
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
crizotinib
Resistant: C4 – Case Studies
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
pazopanib
Resistant: C4 – Case Studies
MDM2 overexpression
Liposarcoma
erdafitinib + RO5503781
Sensitive: D – Preclinical
FGFR1 overexpression
Liposarcoma
erdafitinib
Resistant: D – Preclinical
FGFR4 overexpression
Liposarcoma
erdafitinib
Resistant: D – Preclinical
CDK4 amplification
Liposarcoma
docetaxel + eribulin mesylate
Sensitive: D – Preclinical